hVIVO (LON:HVO) Shares Up 23% - Here's Why

hVIVO plc (LON:HVO - Get Free Report) shares rose 23% on Monday . The company traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.15). Approximately 24,253,932 shares were traded during mid-day trading, an increase of 569% from the average daily volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).

Analysts Set New Price Targets

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research report on Friday, May 30th.

hVIVO Trading Up 3.4%

The business's 50-day simple moving average is GBX 15.92 and its 200-day simple moving average is GBX 17.70. The company has a market cap of £76.07 million, a PE ratio of 4.43 and a beta of 0.97. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86.

hVIVO (LON:HVO - Get Free Report) last posted its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, analysts expect that hVIVO plc will post 1.5492958 EPS for the current fiscal year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.